23:02 , Dec 22, 2017 |  BC Extra  |  Company News

Management tracks: CRISPR, Hua

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) appointed Rodger Novak as chairman of the board. He succeeds Tony Coles, who will remain as a senior adviser. Novak is founder and president of CRISPR, and served...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

ASG-15ME: Phase I data

An open-label, dose-escalation, North American Phase I trial in 37 evaluable patients with metastatic urothelial cancer previously treated with >=1 chemotherapy regimen or who were unfit for cisplatin showed that once-weekly 0.5, 0.75, 1 and...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Enfortumab vedotin: Phase I data

An open-label, dose-escalation, North American Phase I trial in 28 evaluable patients with metastatic urothelial cancer previously treated with >=1 chemotherapy regimen or who were unfit for cisplatin showed that once-weekly 0.5, 0.75, 1 and...
07:00 , Oct 16, 2014 |  BC Innovations  |  Strategy

New CAR shopping

With two papers in the literature this week solidifying the efficacy of CD19-based chimeric antigen receptor T cells, the question now is how many other targets are amenable to the approach. Target selection is among...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Sea Lane Biotechnologies LLC, Astellas deal

Sea Lane granted Astellas' Agensys Inc. subsidiary a non-exclusive, worldwide license to antibodies generated using Sea Lane's ConCIRT libraries. Agensys will be responsible for preclinical and clinical development and commercialization of the antibodies. Astellas referred...
08:00 , Nov 4, 2013 |  BioCentury  |  Strategy

Teva blinks

With a deeply experienced CEO known for executing large, transformational deals, Teva Pharmaceutical Industries Ltd. had the chance to do something disruptive. But after the abrupt departure of President and CEO Jeremy Levin last Wednesday,...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

ASG-5ME: Development discontinued

Seattle Genetics and Astellas disclosed in its 2Q13 and fiscal 1Q13 earnings ending June 30, respectively, that the companies discontinued development of ASG-5ME to treat cancer after "comprehensive consideration" of Phase I data. ASG-5ME was...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Seattle Genetics, Astellas deal

Seattle Genetics exercised a 2007 option from Astellas' Agensys Inc. subsidiary to co-develop and co-commercialize ASG-15ME . Agensys, which received an undisclosed exercise payment, submitted an IND for a Phase I trial of the antibody-drug...
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

Astellas management update

Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan   Business: Pharmaceuticals   Hired: Sef Kurstjens as CMO, a newly created position, formerly president and CEO of Agensys Inc. , which Astellas acquired  ...